Skip to content
naulon

Not checkedNot checked for notices yet.

The evolving role of the renin–angiotensin system in ARDS

Eleni Vrigkou, Iraklis Tsangaris, Stefanos Bonovas and 2 more

Critical Care · 2017

doi:10.1186/s13054-017-1917-5 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

We read with great interest the article by Khan et al. [1] reporting the results of a pilot clinical trial of administrating recombinant angiotensin-converting enzyme 2 (ACE2) in patients with acute respiratory distress syndrome (ARDS).Current research has been focused on the involvement of the renin-angiotensin system (RAS) in the pathogenesis and clinical outcomes of ARDS and, in particular, in the evaluation of the angiotensin-converting enzyme (ACE)/ angiotensin II (Ang II)/Ang II receptor type 1 axis and its counterpart ACE2/angiotensin-(1-7)/MAS1 receptor pathway as potential therapeutic targets.Given the lack of effective pharmacological ARDS treatments, clinical trials exploring new therapeutic strategies, like that by Khan et al.[1], are essential.

Abstract licence: CC BY-NC-ND

References10

  1. 10.

9 more references, whose wording the paper’s licence keeps private.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.